发布求助
文献互助 智能选刊 最新文献

Japanese Journal of Cancer and Chemotherapy最新文献

筛选
英文 中文
[Current Status of Molecular Residual Disease Testing in Genitourinary Cancers]. [泌尿生殖系统肿瘤分子残留病检测现状]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Taigo Kato
{"title":"[Current Status of Molecular Residual Disease Testing in Genitourinary Cancers].","authors":"Taigo Kato","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent advancements of surgery including robotic surgery have improved the clinical outcomes of resectable solid tumors. Although preoperative chemotherapy is often performed for high-risk cancers, the risk of postoperative recurrence remains a critical issue. So far, recurrence has been monitored through periodic imaging tests; however, molecular residual disease (MRD)has caught much attention as the means to detect minimal cancerous lesions at an earlier stage. With the rapid advancements in circulating tumor DNA(ctDNA)analysis using next-generation sequencing, MRD testing is emerging as a promising tool for predicting recurrence in multiple types of cancer. Thus, in this article, we discuss the current status of MRD testing in urogenital cancers and its potential impact on future treatment strategies.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"448-450"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Overview of Current Status of Clinical Development by Molecular Residual Disease(MRD)]. [分子残留病（MRD）的临床发展现状综述]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Shin Kobayashi, Yoshiaki Nakamura
{"title":"[Overview of Current Status of Clinical Development by Molecular Residual Disease(MRD)].","authors":"Shin Kobayashi, Yoshiaki Nakamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In October 2024, \"Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease( MRD)testing\"was issued. MRD is defined as\"molecular residual disease detected by the detection of circulating tumor DNA(ctDNA)prior to the appearance of clinical, biologic, or radiologic evidence of recurrence after curative resection\" and has been strongly associated with recurrence after curative resection across multiple cancer types. The attempt to develop personalized perioperative treatment based on MRD testing has been called the\"liquid revolution\", and competition for development is intensifying worldwide. The MRD testing is expected to be a game changer not only in terms of its validity in predicting recurrence, but also in terms of changing the framework of clinical trials for perioperative treatment development and further promoting the development of new therapies. This paper presents the current status and discusses the near future of clinical development based on MRD testing.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"438-442"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of a Patient with Lung Adenocarcinoma on Hemodialysis Treated with Atezolizumab+Carboplatin+Nab-Paclitaxel]. [阿特唑单抗+卡铂+ nab -紫杉醇治疗血液透析肺腺癌1例]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Junichi Hanaka, Mariko Kasuga, Yoshitaka Sakamoto, Mizuki Hagiya, Jun Nakauchi, Takahito Komiyama, Yugo Fukamizu, Takanori Ohata
{"title":"[A Case of a Patient with Lung Adenocarcinoma on Hemodialysis Treated with Atezolizumab+Carboplatin+Nab-Paclitaxel].","authors":"Junichi Hanaka, Mariko Kasuga, Yoshitaka Sakamoto, Mizuki Hagiya, Jun Nakauchi, Takahito Komiyama, Yugo Fukamizu, Takanori Ohata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 70-year-old man presented with anorexia and cough, and CT showed an infiltrative shadow in the right upper lobe. Bronchoscopy revealed unresectable advanced lung carcinoma(cT4N2M1a, cStage ⅣA). The patient had chronic renal failure due to type 2 diabetes mellitus and had been undergoing hemodialysis for 6 years. Four courses of primary chemotherapy( atezolizumab+carboplatin[CBDCA]+nab-paclitaxel[nab-PTX][atezolizumab 1,200 mg/body weight, CBDCA target AUC=5, nab-PTX 100 mg/m2 every 3 weeks])were administered. Thereafter, 3 courses of maintenance treatment with atezolizumab alone(1,200 mg/body weight every 3 weeks)were administered. At this point, the primary tumor was enlarged, and the patient was diagnosed with progressive disease(PD). After 4 courses of second-line chemotherapy with docetaxel(DTX)+ramucirumab(RAM)(DTX 60 mg/m2 day 1, RAM 8 mg/kg day 1, 15, every 4 weeks), the primary tumor temporarily shrank but then re-expanded; therefore, the patient remained in a state of PD. The general condition deteriorated, and he was referred to the palliative care department where he died peacefully.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"475-477"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Locally Advanced Appendiceal Cancer Successfully Resected after Treatment with mFOLFOX6 plus Bevacizumab]. [mFOLFOX6联合贝伐单抗治疗局部晚期阑尾癌成功切除1例]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Nobuhisa Tanioka, Michio Kuwahara, Takashi Sakai, Yujiro Bunno, Shigeto Shimizu, Toyokazu Akimori
{"title":"[A Case of Locally Advanced Appendiceal Cancer Successfully Resected after Treatment with mFOLFOX6 plus Bevacizumab].","authors":"Nobuhisa Tanioka, Michio Kuwahara, Takashi Sakai, Yujiro Bunno, Shigeto Shimizu, Toyokazu Akimori","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 80-year-old woman presented with lower abdominal distension for the past 3 days. Abdominal contrast-enhanced CT revealed an irregularly shaped mass measuring 80×50 mm in the right lower abdomen, with a contrast effect. The final diagnosis was locally advanced appendiceal cancer with multiple invasions into the adjacent ileum and retroperitoneum. After 7 courses of preoperative chemotherapy with mFOLFOX6 plus bevacizumab, the tumor reduced in size, and laparoscopic ileocecal resection with D3 lymph node dissection was performed 4 months after diagnosis. Histopathological examination revealed appendiceal cancer, tub1-tub2, ypT4aN0M0, pStage ⅡB, with a histological Grade of 2 and a curative degree of A. The patient had no signs of recurrence 2 years and 6 months after surgery without receiving adjuvant chemotherapy. We reported a case of locally advanced appendiceal cancer that was successfully treated with mFOLFOX6 plus bevacizumab as preoperative chemotherapy and was curatively resected without combined resection of surrounding organs, with a discussion of the relevant literature.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"467-469"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Double Cancers of the Gallbladder and Duodenal Papilla]. 胆囊癌、十二指肠乳头癌1例
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Kota Yamamoto, Takahiro Ishimori, Taiki Okada, Takeshi Sasaki, Yumi Mikajiri, Takahiro Terashima, Shunji Kawamoto
{"title":"[A Case of Double Cancers of the Gallbladder and Duodenal Papilla].","authors":"Kota Yamamoto, Takahiro Ishimori, Taiki Okada, Takeshi Sasaki, Yumi Mikajiri, Takahiro Terashima, Shunji Kawamoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 65-year-old man was diagnosed with gallbladder cancer during a medical checkup that revealed liver dysfunction. He was referred to our hospital seeking bloodless treatment due to religious beliefs. Blood tests revealed elevated hepatobiliary enzyme levels, and abdominal echocardiography revealed a broad nodular protuberant lesion in the body of the gallbladder and marked dilatation of the common bile duct. PET revealed marked abnormal accumulation of FDG in the gallbladder mass and duodenal papilla. Based on the imaging findings, double cancers of the gallbladder and duodenal papilla were diagnosed. A subtotal gastric-sparing pancreaticoduodenectomy was performed along with resection of the liver bed, gallbladder, and bile ducts, and D2 regional lymph node dissection. Both of postoperative histopathologic diagnosis were papillotubular adenocarcinoma. The patient has remained recurrence-free for 5 years postoperatively. Double cancers of the gallbladder and duodenal papilla are rare, and we report this case based on a review of the literature.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"479-482"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Current Status of ctDNA-Based MRD Testing in Breast Cancer]. [基于ctdna的乳腺癌MRD检测现状]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Yukinori Ozaki, Hiroji Iwata
{"title":"[Current Status of ctDNA-Based MRD Testing in Breast Cancer].","authors":"Yukinori Ozaki, Hiroji Iwata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Treatment strategies for breast cancer are becoming increasingly complex, necessitating a deeper understanding of the disease and the personalization of therapy based on biomarkers. Circulating tumor DNA(ctDNA)allows for comprehensive tumor assessment in a minimally invasive manner, and therapeutic development in this area is actively progressing. Studies evaluating ctDNA during postoperative follow-up or after neoadjuvant chemotherapy across various breast cancer subtypes have consistently shown that ctDNA detection is associated with a higher risk of recurrence, regardless of the clinical setting. Clinical trials investigating therapeutic interventions guided by ctDNA testing are currently underway. Moving forward, the development of more sensitive assay and effective therapeutic strategies is needed. The clinical application of ctDNA is expected to further advance personalized treatment in breast cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"451-455"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Operational Construction and Effectiveness Verification of an HBV Reactivation Management Protocol for Cancer Chemotherapy Patients Based on Medical Information System Safety Management]. [基于医疗信息系统安全管理的肿瘤化疗患者HBV再激活管理方案的操作构建及有效性验证]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Masato Komuro, Yuri Toda, Sae Ishikawa, Hiroshi Hyakutake, Tomofumi Watanabe, Yumiko Shimanuki, Maho Tanaka, Komei Shimokawa, Takahiro Nishimura, Kengo Miyo
{"title":"[Operational Construction and Effectiveness Verification of an HBV Reactivation Management Protocol for Cancer Chemotherapy Patients Based on Medical Information System Safety Management].","authors":"Masato Komuro, Yuri Toda, Sae Ishikawa, Hiroshi Hyakutake, Tomofumi Watanabe, Yumiko Shimanuki, Maho Tanaka, Komei Shimokawa, Takahiro Nishimura, Kengo Miyo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis B virus(HBV)reactivation during cancer chemotherapy is a life-threatening condition with a high risk of severe or fulminant disease. Effective management is essential; however, individual physicians may lack a structured system for handling HBV-related risks, and both physicians and pharmacists often face significant administrative burdens, including making inquiries, entering orders for additional testing, and verifying appropriate orders. To address this challenge, we developed a pharmacist-initiated, protocol-based pharmacotherapy management system for HBV(PBPM-HBV), allowing pharmacists to order HBV-related tests on behalf of physicians in accordance with the Guidelines for the Safety Management of Medical Information Systems. Implementing PBPM-HBV under these guidelines reduced the number of HBV-related test requests from 224 to 50, resulting in an approximately 75.7% reduction in workload. The introduction of PBPM-HBV at our hospital has improved workflow efficiency for both physicians and pharmacists while ensuring the safety of the medical information system and cancer chemotherapy processes.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"457-461"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Development of Oncolytic Viruses against Cancer]. [抗癌溶瘤病毒的发展]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01
Hiroshi Tazawa, Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara
{"title":"[Development of Oncolytic Viruses against Cancer].","authors":"Hiroshi Tazawa, Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Oncolytic virotherapy is a novel antitumor therapy using genetically modified oncolytic viruses(OVs)that specifically replicate and induce lytic cell death in tumor cells. OVs directly induce tumor cell death and indirectly enhance the antitumor efficacy of chemoradiotherapy by suppressing cell survival signaling. Moreover, OVs activate antitumor immunity by inducing immunogenic cell death and enhance the antitumor effect of immune checkpoint inhibitors. OVs including herpes simplex virus and adenovirus have been widely developed for clinical application. This review focuses on the therapeutic potential of OVs in monotherapy and combination therapy with conventional cancer treatment and summarizes representative OVs that are in the phases of clinical trials.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"431-437"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Remarkable Immune-Cell Therapy Efficacy in a Patient with Renal Pelvic Cancer Refractory to Immune Checkpoint Inhibitors and Chemotherapy]. [1例免疫细胞治疗对免疫检查点抑制剂和化疗难治的肾盂癌患者疗效显著]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01
Rishu Takimoto, Takashi Kamigaki, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Shigenori Goto
{"title":"[A Case of Remarkable Immune-Cell Therapy Efficacy in a Patient with Renal Pelvic Cancer Refractory to Immune Checkpoint Inhibitors and Chemotherapy].","authors":"Rishu Takimoto, Takashi Kamigaki, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Shigenori Goto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 70s-year-old woman with a history of Lynch syndrome had ovarian, colon, and right renal pelvic cancers, all of which were detected early and surgically treated with no recurrence. Ten years have passed since the most recent surgical procedure. In September 2020, she developed hematuria and underwent an examination, which revealed left renal pelvic cancer with liver and lung metastases. Chemotherapy(GEM+CBDCA)was initiated in October 2020; however, imaging in April 2021 revealed disease progression. Treatment with an immune checkpoint inhibitor(ICI: pembrolizumab 240 mg/body)was initiated, but after 4 months, the disease progressed and the treatment was discontinued. The patient was then referred to our hospital. Immunological testing revealed a decrease in T cells; therefore, immune-cell therapy(αβT cell therapy)was initiated to improve this condition. After 4 sessions of αβT cell therapy at 2-week intervals, a CT scan in November 2021 revealed shrinkage of the liver metastases and renal pelvis tumor, and the patient was assessed as having a partial response. By February 2022, after a total of 7 sessions of αβT cell therapy, further tumor shrinkage was observed, and the tumor was almost completely resolved on imaging. Although further immunotherapy is rarely administered in patients for whom ICI is ineffective, our findings suggest the potential for significant immune-cell therapy efficacy even after ICI failure.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"423-426"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Locally Advanced Rectal Cancer in Which Pathological Complete Response Was Achieved with CAPOX and Bevacizumab Chemotherapy]. [局部晚期直肠癌CAPOX联合贝伐单抗化疗病理完全缓解1例]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01
Noriaki Koizumi, Wataru Takaki, Tatsuya Matsumoto, Hiroshi Fujiki, Chouhei Sakakura
{"title":"[A Case of Locally Advanced Rectal Cancer in Which Pathological Complete Response Was Achieved with CAPOX and Bevacizumab Chemotherapy].","authors":"Noriaki Koizumi, Wataru Takaki, Tatsuya Matsumoto, Hiroshi Fujiki, Chouhei Sakakura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 39-year-old man patient was admitted to a nearby clinic with bloody stool. Digital rectal examination revealed a mass lesion in the lower rectum. The patient was referred to our hospital and finally diagnosed with cT4a, N1b, M0, and c-Stage Ⅲb locally advanced rectal cancer. Neoadjuvant chemotherapy(NAC)with CAPOX and bevacizumab was administered to facilitate R0 resection, permitting anal preservation. When the chemotherapeutic regimen was evaluated to have achieved a complete clinical response, the patient underwent laparoscopic low anterior resection. He was shortly discharged without complications. No residual cancer was revealed upon histopathological examination, demonstrating a complete pathological response. Although NAC for rectal cancer has not been recommended by the Japanese guidelines, high response rates have recently been reported. Herein, we present the utility of NAC in the treatment of rectal cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"415-417"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信